These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17200480)

  • 1. Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
    Eikelboom JW; O'Donnell M
    JAMA; 2007 Jan; 297(1):91-2. PubMed ID: 17200480
    [No Abstract]   [Full Text] [Related]  

  • 2. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexelizumab and the APEX AMI trial.
    Armstrong PW; Granger CB
    JAMA; 2007 May; 297(17):1881; author reply 1881-2. PubMed ID: 17473297
    [No Abstract]   [Full Text] [Related]  

  • 5. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Lin GM; Li YH; Jaiteh LE; Han CL
    Am Heart J; 2012 Dec; 164(6):e19; author reply e21. PubMed ID: 23194495
    [No Abstract]   [Full Text] [Related]  

  • 6. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
    Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?
    Beranek JT
    Circulation; 2004 Apr; 109(16):e195-6; author reply e195-6. PubMed ID: 15117866
    [No Abstract]   [Full Text] [Related]  

  • 8. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial.
    Stebbins A; Mehta RH; Armstrong PW; Lee KL; Hamm C; Van de Werf F; James S; Toftegaard-Nielsen T; Seabra-Gomes R; White HD; Granger CB;
    Circ Cardiovasc Interv; 2010 Oct; 3(5):414-22. PubMed ID: 20858863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
    Patel JA; Ghatak SB
    Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):145-52. PubMed ID: 18537766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction".
    French JK; Armstrong PW; Cohen E; Kleiman NS; O'Connor CM; Hellkamp AS; Stebbins A; Holmes DR; Hochman JS; Granger CB; Mahaffey KW
    Am Heart J; 2011 Jul; 162(1):89-97. PubMed ID: 21742094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors.
    Lin GM; Chu KM; Han CL
    Int J Cardiol; 2011 Jan; 146(2):280-2. PubMed ID: 21109318
    [No Abstract]   [Full Text] [Related]  

  • 13. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
    JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
    Fleisig AJ; Verrier ED
    Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.
    Gibson CM; Pride YB
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):61-3. PubMed ID: 20129532
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
    Armstrong PW; Fu Y; Westerhout CM; Hudson MP; Mahaffey KW; White HD; Todaro TG; Adams PX; Aylward PE; Granger CB
    J Am Coll Cardiol; 2009 Apr; 53(17):1503-9. PubMed ID: 19389560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Trendelenburg M; Theroux P; Stebbins A; Granger C; Armstrong P; Pfisterer M
    Eur Heart J; 2010 May; 31(10):1181-7. PubMed ID: 20089518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
    Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study.
    Brener SJ; Moliterno DJ; Aylward PE; van't Hof AW; Ruźyllo W; O'Neill WW; Hamm CW; Westerhout CM; Granger CB; Armstrong PW;
    Eur Heart J; 2008 May; 29(9):1127-35. PubMed ID: 18375399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.